Amgen Q3 2026 results: assessing against DeepValue's cautious thesis

What happened

Amgen reported third quarter 2026 financial results on November 3, 2026, but the press release contains only a headline with no specific figures. The latest DeepValue master report, based on data through early 2026, rated AMGN a 'potential sell' with a base case of $340 and an attractive entry at $295, citing accelerating price and biosimilar pressure on ENBREL, Otezla, Prolia, and XGEVA plus unresolved tax risk and elevated leverage. The report highlighted that the key upside driver, MariTide's Phase 3 obesity program, is still ahead, while policy-driven erosion and capex ramp are near-term certainties. Investors must scrutinize the actual earnings release for revenue growth, margin trends, updated guidance, and any commentary on MariTide or Horizon assets to determine if the thesis has shifted. Without details, the headline alone is insufficient to adjust the cautious stance, and the full filing should be examined for signs of deterioration or improvement.

Implication

Investors should compare reported Q3 revenue, EPS, and guidance against the report's expectations: base case revenue growth ~3-4% and margin ~46%. Key watch items: ENBREL net price decline, Otezla impairment impact, biosimilar erosion in Prolia/XGEVA, Tepezza performance, and any updates on MariTide Phase 3 enrollment or data. If results show faster legacy erosion or weaker Horizon growth, the bear case ($270) becomes more likely; if MariTide updates are positive and growth assets exceed, the bull case ($390) gains credibility. Until then, maintain skepticism and wait for a better entry below $295 as suggested.

Thesis delta

No shift yet as the press release provides no financial details. The DeepValue thesis of 'potential sell' remains valid unless the Q3 results show significant improvements in MariTide or Horizon assets that offset known headwinds. A full review of the financial statements and management commentary is required to determine if the risk-reward has improved.